Skip to content

Vaginal Microbiome and IVF Pregnancy Outcome

Associations Between the Vaginal Microbiome, Inflammatory Status and Pregnancy Outcome - a Prospective, Observational Study in Women Undergoing Frozen Embryo Transfers.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05150639
Enrollment
301
Registered
2021-12-09
Start date
2022-03-18
Completion date
2023-05-26
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Flora Imbalance

Brief summary

The aim of this prospective, observational study is to investigate the prevalence of vaginal dysbiosis among women undergoing IVF procedures in the US. And to investigate the associations between the vaginal microbiome and the pregnancy outcome following IVF.

Detailed description

The present study will evaluate differences in vaginal microbiome composition in pregnant and non pregnant women who have undergone IVF treatment with frozen embryo transfer. Concurrently we aim to identify whether menstrual tissue and Cervicovaginal secretion possess complimentary biomarker information reflecting the immune/inflammatory status of the reproductive tract to determine its impact on pregnancy success following frozen embryo transfer IVF procedure.

Interventions

OTHERIVF

Women planning to undergo frozen embryo transfer IVF procedure will be included. Samples will be obtained, but no study intervention will be applied. Pregnancy outcome data will be obtained, following frozen embryo transfer, to correlate against other data from samples (vaginal microbiome etc).

Sponsors

Freya Biosciences ApS
Lead SponsorINDUSTRY
Boston IVF
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 44 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-44 years * Patients whose written informed consent approved by the Institutional Review Board (IRB) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved. * Women undergoing a planned frozen embryo transfer * BMI between 18.5-35 kg/m2 (both included) * Must be able to understand and read the informed consent form in English.

Exclusion criteria

* Current diagnosis of pathologies or malformations that affect the uterine cavity such as polyps, intramural myoma, adhesions, fibroids or hydrosalpinx. * Any illness or medical condition that is unstable or which, according to medical criteria and Investigator's discretion may put at risk the patient's safety and her compliance in the study. * Participants currently taking antibiotics or with any known condition requiring regular use of antibiotics, that would suggest the participant is likely to need antibiotic treatment during the observational period of this study. * Systemic and/or vaginally applied antibiotic use within the last month prior to screening (except for prophylactic antibiotics related to egg retrieval). * Patients utilizing oral contraceptive pills in the past month * Latex or silicone allergy (Diva Cup and Vaginal Disc)

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of vaginal dysbiosisEvaluated from sample collected 1 week prior to frozen embryo transferThe prevalence (evaluated as % of included population) of vaginal dysbiosis in women undergoing frozen embryo transfer IVF treatment in the US

Secondary

MeasureTime frameDescription
Associations of microbiomeEvaluated from sample collected 1 week prior to frozen embryo transfer and correlated with pregnancy outcomes obtained up until birthThe difference in pregnancy success rates (biochemical pregnancy, clinical pregnancy and live birth) following frozen embryo transfer in women with versus without vaginal dysbiosis

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDenis Vaughan, PhD

Boston IVF

PRINCIPAL_INVESTIGATORDenny Sakkas, PhD

Boston IVF

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026